There has been a tremendous amount of change in the healthcare landscape this past year, but also within the business landscape since 2020. Given this change, we asked the ADVI team about their 2024 healthcare New Year’s resolutions. From expanding existing relationships with clients to seeking out more in-person meetings, focusing more on state issues and CMMI engagement strategies, working with CMS on new coverage programs, and expanding ADVI’s data capabilities, the ADVI team has a busy year ahead.

Learn More

Stay ahead of the curve this year. Get in touch today to gain expert insights and strategic counsel on the evolving healthcare landscape.


CEO insights

Real analysis from people who’ve been there

Why Clinical Laboratories Should Consider Weighing In on CMS and CDC’s New CLIA Request for Information

An opportunity for laboratories to help shape the future of CLIA regulation On July 16, 2026, the Centers for Medicare …

July 27, 2026

RAND/UCLA Modified Delphi Panels

ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …

Caitlin Sheetz, MPH
June 23, 2026

Precision Medicine

The MolDX Technical Assessment: How to Move Your Test from “Not Successful” to Medicare Coverage Success

In the laboratory space, the MolDX Technical Assessment (TA) is often the moment where the gap between “a great test” …

April 9, 2026

Precision Medicine

CRUSH and Genetic and Molecular Laboratories: A Potential Shift in Medicare Oversight

Genetic, molecular, and reference laboratories are closely watching a new Medicare concept known as CRUSH- short for Comprehensive Regulations to …

March 17, 2026

Oncology/biologics Precision Medicine

March Is Colorectal Cancer Awareness Month: Why CMS’s Proposed NCD 210.3 Update Could Accelerate Patient‑Centered Screening Access

Colorectal cancer (CRC) screening saves lives, but only when patients are able to access care in a way that meets …

March 17, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Precision Medicine

A New Era for Cancer Detection Begins with the Sewell MCED Law

We are seeing a long‑anticipated and important policy inflection point.  By now you might have heard that Congress passed the …

February 11, 2026

Uncategorized

How HEOR and Real-World Evidence Are Reshaping Decisions in 2026

By 2026, health economics and outcomes research (HEOR) and real-world evidence (RWE) will look less like a supporting function and …

February 10, 2026

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.